Torrent Pharmaceuticals Ltd (IN:TORNTPHARM)
:TORNTPHARM
TORNTPHARM Stock Chart & Stats
₹3578.85
-₹79.35(-2.33%)
At close: 4:00 PM EST
₹3578.85
-₹79.35(-2.33%)
Day’s Range― - ―
52-Week Range₹3,101.00 - ₹4,479.70
Previous CloseN/A
Volume167.59K
Average Volume (3M)7.49K
Market Cap
₹1.35T
Enterprise Value₹1.37T
Total Cash (Recent Filing)₹10.33B
Total Debt (Recent Filing)₹28.22B
Price to Earnings (P/E)51.3
Beta0.51
Next Earnings
May 21, 2026EPS Estimate
21.85Next Dividend Ex-DateN/A
Dividend Yield0.84%
Share Statistics
EPS (TTM)19.00
Shares Outstanding338,431,850
10 Day Avg. Volume2,743
30 Day Avg. Volume7,494
Financial Highlights & Ratios
PEG Ratio3.66
Price to Book (P/B)14.19
Price to Sales (P/S)9.52
P/FCF Ratio54.58
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)81.35
Revenue Forecast (FY)₹149.84B
Bulls Say, Bears Say
Bulls Say
Revenue Growth & MarginsConsistent top-line growth with a near-50% gross margin indicates durable product economics and pricing power in core therapies. Over 2-6 months this supports reinvestment into sales and R&D and underpins margin resilience against cyclical pressures in generics markets.
Strong Cash GenerationMaterial free cash flow expansion and operating cash conversion show the business reliably turns earnings into liquid resources. This sustainable cash profile funds capex, supports working capital, and reduces refinancing risk while enabling dividends or M&A over the medium term.
Improved Balance Sheet & ROEA strong equity base and reduced leverage provide financial flexibility to pursue growth or weather regulatory setbacks. High ROE indicates effective capital allocation and shareholder returns, supporting durable profitability and capacity for strategic investments.
Bears Say
Net Profit Margin PressureA mid-teens net margin suggests operating expenses or pricing pressure constrain bottom-line conversion. Persistently modest net margins can limit retained earnings and reduce the buffer against price erosion or tougher tender dynamics in international markets over a multi-month horizon.
Asset Utilization HeadroomExplicit scope to improve asset turnover implies capital employed may not be fully efficient. Without better utilization, revenue growth may require disproportionate capital, limiting long-term ROIC improvement and constraining scalable margin expansion versus peers.
Revenue Concentration RiskHeavy reliance on domestic branded generics and partner-led international commercialization exposes the company to pricing, competitive and tender risks in core markets. Limited diversification of revenue streams can amplify regulatory or market shocks over 2-6 months.
Torrent Pharmaceuticals Ltd News
TORNTPHARM FAQ
What was Torrent Pharmaceuticals Ltd’s price range in the past 12 months?
Torrent Pharmaceuticals Ltd lowest stock price was ₹3101.00 and its highest was ₹4479.70 in the past 12 months.
What is Torrent Pharmaceuticals Ltd’s market cap?
Torrent Pharmaceuticals Ltd’s market cap is ₹1.35T.
When is Torrent Pharmaceuticals Ltd’s upcoming earnings report date?
Torrent Pharmaceuticals Ltd’s upcoming earnings report date is May 21, 2026 which is in 46 days.
How were Torrent Pharmaceuticals Ltd’s earnings last quarter?
Torrent Pharmaceuticals Ltd released its earnings results on Feb 13, 2026. The company reported ₹19 earnings per share for the quarter, beating the consensus estimate of ₹18.196 by ₹0.804.
Is Torrent Pharmaceuticals Ltd overvalued?
According to Wall Street analysts Torrent Pharmaceuticals Ltd’s price is currently Overvalued.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd pays a Notavailable dividend of ₹6 which represents an annual dividend yield of 0.84%. See more information on Torrent Pharmaceuticals Ltd dividends here
What is Torrent Pharmaceuticals Ltd’s EPS estimate?
Torrent Pharmaceuticals Ltd’s EPS estimate is 21.85.
How many shares outstanding does Torrent Pharmaceuticals Ltd have?
Torrent Pharmaceuticals Ltd has 338,431,850 shares outstanding.
What happened to Torrent Pharmaceuticals Ltd’s price movement after its last earnings report?
Torrent Pharmaceuticals Ltd reported an EPS of ₹19 in its last earnings report, beating expectations of ₹18.196. Following the earnings report the stock price went down -0.185%.
Which hedge fund is a major shareholder of Torrent Pharmaceuticals Ltd?
Currently, no hedge funds are holding shares in IN:TORNTPHARM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Torrent Pharmaceuticals Ltd
Torrent Pharmaceuticals Limited engages in the research, development, manufacturing, and marketing of generic pharmaceutical formulations in India, the United States, Germany, Brazil, and internationally. It offers products in various therapeutic areas, including cardiovascular, central nervous system, gastrointestinal, women healthcare, diabetology, pain management, gynecology, oncology, and anti-infective, as well as provides vitamins, minerals, and nutrients. The company also provides contract manufacturing services. It has licensing collaborations of Baricitinib, Molnupiravir, and Paxlovid for its Covid portfolio. Torrent Pharmaceuticals Limited was formerly known as Trinity Laboratories and changed its name to Torrent Pharmaceuticals Limited in 1971. The company was founded in 1959 and is based in Ahmedabad, India. Torrent Pharmaceuticals Limited is a subsidiary of Torrent Investments Private Limited.
Technical Analysis
Cipla Ltd
―
Divi's Laboratories Limited
―
Dr. Reddy's Laboratories Ltd.
―
Lupin Limited
―
Zydus Lifesciences Limited
―